• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1267518 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
4 ]! P' |; K9 g, s7 U! X& ^+ ^NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 , O. c/ ~. S/ Q7 e6 p
+ Author Affiliations
( ]1 z6 f9 V/ j; G4 s4 I$ ?% m
$ \' F' \: s$ {+ @, Q' U1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
9 E+ d) f% J; F) [/ S: G+ j0 f2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
& q8 s: h8 y; s$ @  g7 q3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 8 B" O* _! \; s6 z+ V
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
. ~* q; h/ |- C; J4 [5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
6 e0 V: f$ `7 a( p" Y& V" E, `9 {6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
7 l# z( A% Z2 U0 Y7 |1 A0 K$ \8 b7Kinki University School of Medicine, Osaka 589-8511, Japan 1 g8 b% Q& h1 Y
8Izumi Municipal Hospital, Osaka 594-0071, Japan 2 D2 p% m3 ^! c6 N' U
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
) r' K: S! `( \2 p, @4 @0 \Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
+ w% F5 v% c  h4 w. q+ _6 L6 G; ~AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
6 @# m3 [- X# w  ?& O  P% x3 ^
# x. Z7 h' m, g/ o; {; K
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type ' U. T. P% [1 J1 |
; h; V: h  n" u- Z3 h
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato ) y5 j2 _4 O3 @0 e, |2 r
4 J/ A2 U- u$ q% w* g0 C  P
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  5 g6 p8 P( r# O7 z+ V/ c2 M
+ o- K3 n+ f  r- T. Y
Published online on: Thursday, December 1, 2011 6 s( u! |7 H$ Q* u6 l+ s

8 w# G% x! n+ d+ ~5 k0 ^0 D" KDoi: 10.3892/ol.2011.507 . |* t. |+ V) u! T0 Q  U6 d
& L3 j* Y8 ?6 W) Q6 W  i9 @
Pages: 405-410 ( n/ V4 h+ h4 S# ]( D4 x% W
% n2 g1 V- I; o  o
Abstract:
8 N8 e# q7 e2 AS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma., v. A1 I0 R! ]4 X/ c) J

' Y# X2 k& F8 r- t
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population5 S" {8 O+ Z6 F& }
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
/ x. V* A; Y9 z( G0 f+ Author Affiliations
  a8 d% F. z- P0 G# T1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
+ }7 g! J2 R' N" F2 m7 G2Department of Thoracic Surgery, Kyoto University, Kyoto
( a! @( W& r, N! U- j% m/ v" Y! F) W3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan # r0 V: \( U% a3 w
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
2 n; P2 ]7 x# ~Received September 3, 2010. # }! n" F2 H0 n1 I8 s6 S
Revision received November 11, 2010. 0 H& m1 q' J' o$ ~9 ^
Accepted November 17, 2010. + c0 ~$ B: ]  [- s- d
Abstract" P' d" H3 D! O( l) t
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. & j! h& u* w, w9 Y7 K1 v- Z+ `
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
9 r: O1 m' F$ R- ?% U/ y+ ^1 G$ NResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. . ~  V1 }$ ^2 j7 m9 L' M4 d' z2 V
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 3 r5 J& s  R6 a' s* e
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
! Z  B% k+ M, }( R/ t今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?3 \  h6 B- c) Q+ x# b0 M6 N. b
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
% w+ p# k' k& N) chttp://clinicaltrials.gov/ct2/show/NCT01523587
) ~3 t! u; b  t2 F2 O4 P/ i! C% C. g- a5 ^
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
0 a$ T6 b; n: ]) l2 ^. m$ khttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 - K5 \' g7 }& s6 ^# Z. V

0 K* P" q5 J: S( O0 q& L2 u' Q+ W6 V从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。) @2 H0 @# Z& B. a" S( `. O$ F+ r
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
, k3 @5 Q) s7 r9 A4 b4 f! T* d
没有副作用是第一追求,效果显著是第二追求。: K7 P5 K+ G$ p* H& n
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表